ClearPoint Neuro announces first patient enrolled in trial using Prism system

ClearPoint Neuro announced enrollment of the first patient in a Glioblastoma clinical trial using the ClearPoint PrismNeuro Laser Therapy System at Skundefinedne University Hospital in Lund, Sweden. The Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions study, sponsored by Clinical Laserthermia Systems ABis a single-center, single-arm, prospective clinical trial evaluating the safety and feasibility of using the minimally invasive MR-guided laser therapy system to ablate tumor in up to five Glioblastoma patients. The SUS Lund team is also currently utilizing the ClearPoint Neuro Navigation platform for standard of care procedures, including tumor biopsy and guiding implantation of deep brain stimulation electrodes to target. ClearPoint Neuro has exclusive global rights to commercialize the ClearPoint Prism Neuro Laser Therapy System from CLS for neuro applications. The system comprises a clinical solution combining the ClearPoint navigation platform, the laser technology from CLS, and a thermal ablation monitoring software called Thermoguide from Image Guided Therapy. In September of this year, CLS received FDA clearance for the ClearPoint Prism Neuro Laser Therapy System. Data from this trial will be utilized by CLS to secure CE Mark in Europe.